Drug maker Lupin Ltd is expected to soon launch its generic version of the anti-HIV drug, Combivir, in the United States. The move was likely to lend a significant upside to the Mumbai-based company’s bottom line in the forthcoming quarters, a source said.
Lupin’s drug, a combination of lamividine and zidovudine tablets, is a generic version of Viiv Healthcare’s Combivir that is prescribed in combination with other antiretroviral agents for the treatment of HIV-1 infection. “Lupin is likely to launch generic Combivir in the US as early as this month,” the source said. The 1968-founded company is waiting for the final approval from the US Food and Drug Administration (FDA).